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Abstract
Mass treatment as a means to reducing P. falciparum malaria transmission was used during the first global malaria
eradication campaign and is increasingly being considered for current control programmes. We used a previously
developed mathematical transmission model to explore both the short and long-term impact of possible mass treatment
strategies in different scenarios of endemic transmission. Mass treatment is predicted to provide a longer-term benefit in
areas with lower malaria transmission, with reduced transmission levels for at least 2 years after mass treatment is ended in
a scenario where the baseline slide-prevalence is 5%, compared to less than one year in a scenario with baseline slide-
prevalence at 50%. However, repeated annual mass treatment at 80% coverage could achieve around 25% reduction in
infectious bites in moderate-to-high transmission settings if sustained. Using vector control could reduce transmission to
levels at which mass treatment has a longer-term impact. In a limited number of settings (which have isolated transmission
in small populations of 1000–10,000 with low-to-medium levels of baseline transmission) we find that five closely spaced
rounds of mass treatment combined with vector control could make at least temporary elimination a feasible goal. We also
estimate the effects of using gametocytocidal treatments such as primaquine and of restricting treatment to parasite-
positive individuals. In conclusion, mass treatment needs to be repeated or combined with other interventions for long-
term impact in many endemic settings. The benefits of mass treatment need to be carefully weighed against the risks of
increasing drug selection pressure.
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Introduction
In the last few decades, antimalarial drugs that act against
Plasmodium falciparum have been used primarily to avert severe
morbidity and mortality. However, antimalarials have also been
given to asymptomatic parasite carriers, particularly during
historical malaria eradication programmes in the 1950s–1970s,
with the aim of preventing onward transmission to mosquitoes and
potentially interrupting transmission [1]. During the ongoing scale
up of malaria interventions, a number of control agencies are
reconsidering or piloting a mass treatment approach to aid
transmission reductions (for example [2]). However past pro-
grammes had mixed success and were linked to increases in drug
resistance [3,4], as well as requiring a relatively high level of
resources. The intervention is not currently recommended by the
World Health Organization, although there is interest in further
research [5,6]. Given the potential drawbacks, it is important to
better understand the extent to which this intervention could
reduce transmission across different endemic settings.
Mass drug administration (MDA) involves distributing a
curative regimen of antimalarials to each member of a population,
regardless of the presence of parasitaemia or symptoms suggestive
of malaria, while mass screening and treatment (MSAT)
programmes treat only parasitaemic individuals. In theory, the
malaria parasite may seem vulnerable to a mass treatment
programme which targets the infectious reservoir in humans.
The lifespan of malaria vectors is at most a few weeks and there is
no significant animal reservoir of falciparum malaria. In practice,
however, some individuals do not participate in mass treatment
(due to refusal or health conditions that preclude antimalarial
treatment, for example), and drugs may reach ,95–98% efficacy
but are not 100% efficacious even where there is no resistance [7].
Remaining parasite carriers can then be the source for re-
establishment of malaria transmission, potentially rapidly. Past
MDA interventions have been extensively reviewed [1]. The
impact of these programmes is difficult to assess because (1) MDA
was usually combined with simultaneous vector control, (2) few
trials had sufficient if any control populations since most were
conducted before the development of cluster-randomized trial
methodology and (3) measurement of impact on transmission was
frequently carried out for too short a time after the MDA. These
limitations notwithstanding, most trials report at least a transient
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effect on malaria transmission, although in some cases this was
very small or of short duration [8]. Four studies reported local
elimination of malaria at least for a number of years [9,10,11,12];
all of these combined MDA with indoor residual spraying.
However a mass administration of pyrimethamine in Tanzania
was followed shortly afterwards by the appearance of clinical
resistance in the population [3]. The increased selection pressure
on parasites is likely to be an important drawback of mass
treatment.
Control agencies working on other infectious diseases have
more recent and extensive experience with mass treatment
programmes [13]. For example, large cluster-randomized trials
have been carried out to assess the impact of MDA programmes
on trachoma transmission and theoretical insights have been
gained from mathematical modeling [14]. Mass treatment
programmes for trachoma can achieve a reduced prevalence for
around 2 years following a single round of treatment. However, in
most places, transmission returned to pre-intervention levels over
time in the absence of further intervention [15,16].
There are several questions which need to be addressed to
inform researchers and policy makers who are considering
piloting mass treatment for malaria control. It would be useful
to know whether mass treatment is best used during initial stages
of control programmes to aim for large reductions in
prevalence, or to clear remaining infections after other control
measures have already reduced transmission. Screening before
treatment may be preferred to reduce the number of treatments
required and to prevent unnecessary risk of adverse reactions in
uninfected individuals. However this would be logistically more
demanding and may not have the same impact as an MDA
programme. The advantage of using treatments with gameto-
cytocidal and prophylactic effects has been discussed but the
difference in impact of mass treatment between different types
of antimalarials has not been formally tested. It would also be
helpful to know to what extent mass treatment could have a role
in elimination as part of a wider control programme, and in
what settings this could be achieved. Mathematical models of
mass treatment for malaria have examined the influence of
transmission intensity and seasonal timing of the intervention
[17,18,19]. One model successfully predicted the local elimina-
tion of falciparum malaria by 9 rounds of MDA in a specific low
transmission island setting (Aneityum in Vanuatu) in combina-
tion with insecticide-treated nets [12,20]. We use a recently
published individual-based model which was developed to look
at the impact of multiple interventions [21], and includes
additional aspects of malaria epidemiology which have been
found to be important to accurately estimate reductions in
transmission, such as heterogeneity in exposure to bites in the
human population [22]. Here we characterize the influence of
mass treatment on malaria transmission dynamics using this
model and explore the impact of different strategies for the
implementation of mass treatment.
Methods
Transmission model
We use a previously described dynamic individual-based
stochastic model [21] which captures key aspects of the P.
falciparum lifecycle and its transmission between human and
mosquito populations. The baseline model and its parameters in
the absence of control interventions have been validated by
statistical fitting to data from a wide variety of endemic settings.
Here we summarize key aspects of the model. Parameters are as
previously described, except those shown in Table 1 which have
been added or modified to describe the mass treatment
intervention in more detail.
Humans are categorized into one of 6 states: susceptible and
uninfected S; symptomatic and infectious D; asymptomatic and
infectious A; infectious and undetectable by standard microscopy
U; treated and infectious T; uninfected and protected by
antimalarial prophylaxis P. Newly infected humans develop patent
parasitaemia after a time delay representing the liver stage of the
parasite. A proportion of those infected develop symptoms and
may be successfully treated with an antimalarial, with a subsequent
period of protection against new infections of a duration
dependent on the half life of the antimalarial. In the absence of
treatment or following treatment which does not fully clear
parasitaemia, symptomatic individuals progress to asymptomatic
infection. Asymptomatic infections in state A progress to the
subpatent state U (see below for more detail). We allow for
superinfection in those who are infected. Based on parameter
fitting we assume that the symptomatic, untreated state D results in
the highest probability of human-to-mosquito transmission, after a
fixed delay period allowing for the development time of
gametocytes. Asymptomatic cases A are approximately 3-fold less
likely to infect a biting mosquito, and the subpatent stage U
approximately 17-fold less likely [21]. The infectivity of treated
infections before parasite clearance depends on the antimalarial
used and the state of infection prior to treatment (see below for
details). Among symptomatic cases receiving treatment we assume
a constant 20% coverage of artemisinin-combination therapies
(ACTs) and 80% coverage of non-ACT treatments (such as
sulphadoxine-pyrimethamine) [23]. The non-gametocytocidal
treatments are assumed to resolve symptoms but to be only 60%
efficacious at clearing parasites, due to resistance, while ACTs are
assumed to be 95% efficacious. Treatment failures enter the
asymptomatic A state.
The human population model is fully age-structured. It allows
for three types of immunity: infection-blocking which reduces the
probability of becoming infected following a bite from an
infectious mosquito; clinical immunity which reduces the proba-
bility of developing symptoms upon infection, and blood-stage
immunity which speeds recovery from the asymptomatic, patent
state. We also allow for heterogeneous exposure among humans to
mosquito bites. The human and vector populations are assumed to
be static, with no possibility for reintroduction of infection by
migration. We assume a human population size of at least 10,000
and average over a minimum of 10 stochastic realizations, unless
otherwise indicated. Simulations using this population size closely
approximate results from simulations of larger populations
(confirmed using a population size of 250,000, results not shown).
As previously described, the vector population is modeled with a
seasonally-forced Susceptible-Exposed-Infectious (SEI) structure.
Vectors are assumed to have characteristics of Anopheles gambiae s.s.
except in simulations comparing the model to trial data (see
below).
Interventions
As previously described, we assume an MDA programme treats
a percentage of individuals in the population regardless of
infection status. For simplicity, treatment is assumed to occur in
all individuals instantaneously. Those who are uninfected at the
time of mass treatment enter the protected state P for a time
dependent on the half life of the drug, with a probability
dependent on the efficacy of the drug (defined as the probability
of full parasite clearance). Infected individuals who are successfully
treated by the MDA progress to the treated, infected state T and
clear parasites more quickly, and may also enter the protected
Mass Treatment for Malaria Control
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state after recovery depending on the half life of the drug. AnMSAT
programme is implemented in the same way in the model except
that it is given to individuals selected by screening tests. If PCR is
used as the screening tool, those in the infected A, D andU states are
treated, while if microscopy is used, only those in the D and A states
are treated. The model was previously fitted to detailed data
available on the prevalence of microscopy-positive infection versus
PCR-positive infection by age, with PCR detection assumed to be
the gold-standard method [21]. These data suggest a sensitivity of
microscopy around 50–75%. Under these model assumptions, the
most infectious individuals (D and A) are identified and treated
during an MSAT programme using microscopy (Table 1). In
sensitivity analyses, we also modeled MSAT assuming the screening
test would have 75% or 50% sensitivity to detected infected
individuals regardless of whether in the D, A, or U states, since the
sensitivity of microscopy can vary widely [24].
We contrast the impact of using antimalarials with different
properties for mass treatment: non-gametocytocidal antimalarials
such as sulphadoxine-pyrimethamine-amodiaquine (SP-AQ) ver-
sus gametocytocidal antimalarials such as combinations containing
artemisinin (ACT) or artemisinin and primaquine (PQ); and short-
acting antimalarials such as lumefantrine versus long-acting
antimalarials such as SP or piperaquine. Sources for parameters
describing antimalarial effects are given in Table 1 (see Text S1 for
further detail). We model a constant percentage reduction in
infectivity of infected individuals by a given treatment compared to
the infectivity of the state occupied in the previous time step. We
assumed all antimalarials used for mass treatment would
successfully clear parasites from 95% of infected cases to give a
fair comparison of their pharmacodynamic properties, although
this may not be the case particularly for non-ACT treatments such
as SP-AQ in many endemic areas.
As previously [21] we considered the likelihood that when
multiple rounds of mass treatment are carried out, the same
individuals may be repeatedly less likely to participate, which
could reduce the impact of the intervention. The correlation in the
probability of participating in successive rounds of the intervention
can be between 0 (mass treatment is distributed randomly in the
population) and 1 (the same individuals always participate or never
participate in mass treatment). Modern mass treatment pro-
grammes may not include pregnant women for safety reasons. For
these simulations we assumed that women of child-bearing age
would be tested for pregnancy and excluded from treatment upon
a positive test result. We estimated prevalence of pregnancy based
on fertility data from 25 Sub-Saharan African countries (see Text
S1). For simplicity we did not assume any difference in
susceptibility of infection among pregnant women compared to
other adults. Since mass treatment would rarely be used as a single
intervention, we also explored the impact of a programme in
which vector control is used simultaneously (details are given in
Text S1 and previous publication [21]). Further details of the
model methods are given in Text S1.
Outcomes
We assess the impact of mass treatment over time on both the
EIR and prevalence of infection detectable by microscopy of blood
slides. We report the cumulative EIR or prevalence reduction
which is the sum of the reduction each day compared to pre-
intervention levels over the specified number of days. We also
examined the probability of local elimination in the model in
populations of different sizes from 500 stochastic realizations for
each scenario to identify the proportion in which elimination
occurred. For results where we were interested in the average
outcome in a population over the long term we also considered as
an outcome a pre-elimination stage, which was defined as a
scenario where slide-prevalence ,0.1% for at least 50 days. The
pre-elimination outcome was used because the outcome of full
elimination in large populations in the long term is sensitive to the
Table 1. Key parameters used in the model with references.
Definitions & units Estimates (data/literature)
Values used
in model
Drug efficacy (% treated individuals with no parasitological
treatment failure, all drug types)
ACT 95–98% [7] 95
Duration of gametocytaemia in treated infection, days
non-artemisinins 55.6 [43] 55.6
ACT 13.4 [43] 13.4
ACT-PQ 3.0 [43] 3.0
Duration of inhibitory antimalarial blood concentration, days
‘Short-acting’ drug 7 SP N51I, S108N mutant, partially resistant [46] 10
8.5–12.4 lumefantrine [47]
‘Long acting drug’ 30 SP, low prevalence of resistant strains [48] 30
% reduction in average infectiousness following treatment
compared to state occupied prior to treatment
non-artemisinins 70 based on [42] 70
ACT, ACT-PQ 80.6 [49] 80.6
Pregnancy prevalence
Among women aged 15–45 14.2% based on [50] -
Among the population aged 15–45 - 7.1%
Correlation in individual participation between repeated rounds of MDA - 0.5
Parameters listed here are those which are additional or different from the previously published model [21].
doi:10.1371/journal.pone.0020179.t001
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assumed time-scales of decline of immunity following reduced
exposure, which are uncertain [25] as well as large-scale spatial
heterogeneity in transmission which is not currently considered in
the model.
Trial data
We compared our model output with results of a field trial of
MDA which took place in Burkina Faso in 1960–1961 [26]. 5
villages (1890 people) received 8 rounds of MDA at 28 day
intervals, 3 villages (2560 people) received MDA every fortnight
for a total of 15 rounds and there were 6 control villages with no
intervention. Within villages, individuals were randomized to
receive chloroquine-primaquine or amodiaquine-primaquine. We
fitted our model to the measured seasonal entomological
inoculation rate (EIR) using maximum likelihood and compared
our output to the slide-prevalence in 2–10 year olds before, during
and after the intervention period (see Text S1 for full details).
Results
Rebound in transmission following mass treatment &
comparison with trial data
The predicted impact of a MDA programme with one round of
treatment and no screening criteria is shown (Figures 1A & 1B,
Table 2). Unless otherwise indicated, we assume in all results that
an ACT with a short half life is used for mass treatment and that
coverage is 80%. Immediately following MDA there is a dramatic
drop in slide-prevalence due to successful cure of infection.
However transmission of the parasite can on average persist in the
population in the scenarios shown, given that mosquitoes remain
infected, treated cases transmit to mosquitoes for some time after
treatment, coverage is not 100%, and treatment efficacy is not
100% even in the absence of drug resistant parasites (e.g. due to
incomplete drug absorption). The prevalence of infection is
therefore predicted to rise again following MDA until it eventually
reaches the pre-intervention level, as found in previous analyses
[18]. The reason for this is that the key factors which determine
local transmission intensity and therefore prevalence of infection
are the local density of mosquitoes, their rate of biting humans,
and the rate at which infected humans clear parasitaemia. Once
inhibitory blood drug levels decline in those participating in the
mass treatment none of these factors have been changed
permanently, in the absence of any other control interventions.
Figures 1A–1B and Table 2 show the average predictions of
impact in a large population. In a later section, we consider the
potential for temporary local elimination in smaller populations
due to chance events.
The impact of MDA in the short and long term depends on the
initial level of transmission in an area (Figures 1A & 1B, Table 2).
In the short term, if 80% of randomly-selected individuals are
treated in any given population, there will naturally be higher
absolute numbers of infected individuals cured directly by the
MDA if 50% of people are infected than if 5% of people are
infected. However the long term duration of MDA impact is
predicted to be much longer in low transmission settings, as found
in previous analyses [14,18]. In the low transmission scenario
(baseline slide-prevalence = 5%) without seasonal variation in
transmission, the prevalence of infection takes around 3 years to
return to baseline. By contrast in areas of high transmission,
frequent vector biting means that parasites surviving after mass
treatment are spread rapidly through the population. We find that
in a high transmission scenario of 50% baseline slide-prevalence,
levels of infection return close to baseline within 7 months after a
single round of MDA (Figure 1A). The cumulative impact of the
intervention over time in terms of the absolute number of
infectious bites averted per person is highest in the high
transmission scenario, where a round of MDA is estimated to
prevent 27 infectious bites per person compared to 0.3 infectious
bites per person in the low transmission scenario over the 2 years
following the interventions (Table 2). However in the high
transmission scenario the reduction amounts to only 9% of total
infectious bites received over the 2 years, while in the low
transmission scenario 35% of infectious bites are prevented
(Table 2). The reduction in the number of days spent infected
shows a similar pattern. The same rebound effects can be seen in
seasonal transmission settings (Figure 1B).
The model was able to reproduce the results of a previously
published MDA trial [26] reasonably well for the time period in
which EIR data were available although the predictions varied
according to the model assumptions (Figures 1C and 1D).
Prevalence was lower in some intervention villages before the
start of MDA (Figure 1C), although it is not clear if this resulted
from a long-term difference in transmission intensity between
control and intervention villages or chance variation. During
MDA, prevalence reduced substantially in both intervention
groups but 3 months after the end of MDA, prevalence rose
rapidly and reached a level close to that in control groups. Based
on the reported EIR, the model prediction of slide-prevalence was
higher than observed in the data in all trial arms (see Text S1). The
model was previously fitted to a large number of paired EIR and
prevalence data points [21] but there is variability in the
relationship between these measures across age groups and
geographic sites and EIR measurements are imprecise. Therefore
we also ran simulations in which we reduced average annual
mosquito densities (keeping the seasonal pattern and the ratio of
An. gambiae to An. funestus constant) to match the observed
prevalence in the control villages. This matched the intervention
group prevalence data better at the baseline and during the MDA
intervention, although worsened the fit at the follow up measure
(see Text S1). Assuming a lower efficacy of treatment further
improved the model prediction (Figures 1C & 1D), except for
some outlying values in the MDA group who were treated every
28 days (Figure 1D). After the intervention was stopped,
prevalence rose more quickly in the data than was predicted by
the model. However EIR data were lacking for this time period
and control prevalence was also higher than predicted based on
the EIR at the same time during the year before, suggesting that
the annual EIR in the second season may have been higher than in
the first season. Full details and sensitivity analysis are given in
Text S1.
Choice of MDA strategy
Timing. To explore optimal timing of MDA in a seasonal
setting we considered scenarios with different degrees of
seasonality in transmission (Figure 2A). We find that the greatest
cumulative impact on EIR is generally achieved when MDA is
carried out prior to the rise in EIR at the start of the higher
transmission season, in line with previous analyses [18] (Figure 2B).
The worst time to carry out an MDA is predicted to be at the peak
of the transmission season or just beforehand (Figure 2C), since
high transmission rates at this time allow the parasite prevalence
levels to recover quickly. The cumulative number of infectious
bites prevented per person in the two years following MDA in our
moderate transmission scenario is 2 if MDA is done at the
optimum time (Figure 2B) and 0.1 if done at the least effective time
(Figure 2C).
Choice of antimalarial: gametocytocidal and long-acting
antimalarials. We explored the use of antimalarials with
Mass Treatment for Malaria Control
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different properties for MDA (Figure 2D) in scenarios of high,
medium and low transmission intensity (as in Figures 1A & 1B). We
estimate that using a short-acting ACT for MDA could produce a
24–26% higher reduction in EIR than a short-acting non-
gametocytocidal antimalarial, while a short-acting ACT-
primaquine combination could achieve a 34–35% higher impact.
We also find that a long-acting antimalarial regimen which provided
prophylaxis would give a small advantage over a short-acting
antimalarial (a 2–11% higher cumulative EIR reduction, with greater
effect in the medium and high transmission scenarios). A long-acting
ACT is predicted to give the highest impact, with a 47–63% higher
cumulative reduction in EIR than a short-acting non-
gametocytocidal antimalarial. However long-acting antimalarials
may enhance the development of resistance (see discussion).
Mass Screen and Treat (MSAT) versus Mass Drug
Administration (MDA). MSAT is predicted to have a slightly
lower impact than MDA (Figure 2E). The cumulative reduction in
infectious bites per person over the year following a single round of
MSAT with PCR as the screening tool was estimated to be 84% of
the reduction achieved by MDA. Using microscopy as a screening
tool during MSAT can further reduce the predicted impact
depending on the assumed sensitivity of microscopy. If all those in
the more infectious states A and D were detected and treated, the
transmission reduction was 81% of that achieved by MDA, only
slightly lower than with a programme using PCR as a screening
tool which also treats those in the subpatent U state. The lower
impact of MSAT compared to MDA is explained mostly by the
lack of prophylaxis in screen-negative individuals rather than by
missing subpatent infections under these model assumptions.
However if microscopy detected 75% or 50% of all infected
individuals regardless of infection state, the impact was 60% or
37% of that achieved by MDA, respectively.
Potential for local elimination by mass treatment
We investigated what intensity of mass treatment programme
would be required for elimination of infection in the simulated
population. For all results presented in this section we assumed a
low level of existing vector control prior to mass treatment that
had reduced slide-prevalence of infection by 20–30% from its
initial level (see Text S1). We then assume that this level of vector
control is either maintained or scaled up. The relationship
between the frequency at which mass treatment is repeated and
the potential for control and elimination of infection in large
populations has been previously characterized in relation to
trachoma control [14]. If MDA rounds are repeated indefinitely,
and each successive round of MDA can be carried out before the
prevalence of infection has recovered following the previous
MDA round, the parasite could theoretically be eliminated
Figure 1. Rebound in transmission following mass treatment & comparison with trial data. (A) & (B) Typical MDA model output over time
in scenarios of (A) non-seasonal and (B) seasonal transmission with different baseline transmission intensities: high: baseline average annual slide-
prevalence= 50% (dark blue); medium: baseline slide-prevalence = 15% (mid-blue); low: baseline slide-prevalence= 5% (light blue). A single round of
MDA is carried out at year 0 at 80% coverage (actual coverage is lower due to exclusion of pregnant women). Gray dashed lines indicate predicted
prevalence in the absence of MDA. (C) & (D) Comparison of model predictions with trial data [26]: slide-prevalence in 2–10 year olds in control villages
and intervention villages with MDA carried out (C) every 14 days or (D) every 28 days. Blue line = average model-predicted values in control villages;
dark red line =model predicted value in MDA villages; shaded areas = range of 20 simulations of control and MDA prevalence; blue
circles = prevalence data in control villages; orange triangles = prevalence data from chloroquine-treated individuals in MDA villages; orange
squares = prevalence data from amodiaquine-treated individuals in MDA villages.
doi:10.1371/journal.pone.0020179.g001
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(Figure 3A). The maximum time interval between successive
rounds of treatment so that slide-prevalence on average reaches a
pre-elimination threshold of 0.1% is called the critical interval.
The critical interval depends on speed of resurgence in
transmission and therefore the initial transmission intensity
(Figure 3B). Where slide-prevalence of infection is low (,5%),
six-monthly rounds of MDA or MSAT using PCR screening are
predicted to be sufficient to bring prevalence to the pre-
elimination threshold (Figure 3B). In medium-to-high transmis-
sion settings, treatment would need to be highly frequent to
achieve this target with either strategy. These results in medium-
to-high transmission settings are also sensitive to the assumed
level of repeated non-participation: if a sufficiently large
proportion of the population never participated in mass
treatment then however frequently mass treatment was carried
out it would not be sufficient to reduce prevalence to zero. In
medium-to-high transmission settings, less frequent rounds of
mass treatment could sustain an appreciable impact on
transmission if they were ongoing (Figure 3C). For example,
annual MDA is estimated to lower mean EIR by 20% where
baseline slide-prevalence is 40%, while six-monthly treatment
rounds could achieve a 30% reduction in the same scenario.
As well as examining average outcomes in large populations, we
explored chance elimination on a local scale in populations of
different sizes using multiple stochastic simulations (example
shown in Figure 3D). However, this outcome applies only to
specific scenarios in the short-term since (1) we do not consider
immigration of new infections into our human or mosquito
populations and (2) elimination is highly dependent on the
assumed population size (e.g. see [27]).
In small populations where malaria transmission has already
been brought to a low level, a single round of mass treatment could
appreciably raise the probability of elimination. For example in
settings with 4% slide-prevalence, we find that the probability of
chance parasite extinction in a human population of 1000 rises
from 15% without any new interventions to 32% or 40% with an
MDA coverage of 80% or 90%, respectively (Figure 3E). However
elimination probabilities are strongly dependent on population size
and initial transmission intensity, so that with a larger population
size (n = 10,000, Figure 3F) or higher starting transmission level,
one treatment round becomes highly unlikely to eliminate
infection. An intense attack on transmission using 5 rounds of
fortnightly MDA boosts the chance of local elimination, with the
probability rising to .30% for settings of ,8% slide-prevalence
and a population size of 1000, however it remains close to zero in
a larger population of 10,000 (Figure 3F).
Scaling up vector control together with MDA raises the
probability of elimination above what would be achieved with
either strategy alone. We assume that a scaled-up vector control
programme would approximately halve slide-prevalence of
infection 2 years after its introduction in most scenarios when
used alone (simulations suggest this could be achieved by raising
insecticide-treated net coverage to 80%, see Text S1). MDA can
speed up the reduction in slide-prevalence (Figure 4A) and while it
does not in the long-term produce a lower prevalence than would
be achieved by vector control alone, prevalence can be brought to
low levels for a period of time which raises the chance of
elimination. For example in a population of 1000, estimated
probabilities of elimination of .40% could be achieved in settings
of up to 25% baseline slide-prevalence by 5 rounds of MDA
Table 2. Short-term and long-term impact of a single round of MDA.
Outcome & setting Absolute number % of total
Cases cured by direct effect of MDA per 100 treated
( = prevalence6coverage (deducting pregnant women)6drug efficacy)
High transmission 35.3 70.6%
Medium transmission 10.6 70.6%
Low transmission 3.5 70.6%
Duration of impact on transmission intensity
(months to return to 90% of baseline slide-prevalence)
High transmission 7 -
Medium transmission 19 -
Low transmission 35 -
Cumulative EIR reduction over the 2 years following MDA
(infectious bites averted per person)
High transmission 26.7 9%
Medium transmission 1.2 22%
Low transmission 0.3 35%
Cumulative prevalence reduction over the 2 years following MDA
(days of infection averted per person)
High transmission 37 10%
Medium transmission 27 27%
Low transmission 13 41%
An MDA programme is simulated which uses a short-acting ACT with 80% coverage (before exclusion of pregnant women) in 3 areas with different initial transmission
levels: high (baseline slide-prevalence = 50%), medium (baseline slide-prevalence = 15%) and low (baseline slide-prevalence = 5%). Results are shown for scenarios which
have no seasonal variation in transmission (as in Figure 1A).
doi:10.1371/journal.pone.0020179.t002
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together with simultaneous scale-up of vector control (Figure 4B).
However in a larger population of 10,000, the probabilities using
the same strategies would be considerably lower (Figure 4C) and
would approach zero in a population of 500,000 (Figure 4D).
Discussion
Our simulations suggest that given a favorable set of
circumstances, mass treatment has the potential to be a valuable
part of a malaria control programme. Specifically, where
transmission rates are relatively low (,5% slide prevalence), a
single round of mass treatment could lower transmission for 2
years or more. Seasonal variation in transmission can be exploited
to maximize impact. Mass treatment could also appreciably
increase the chance of local elimination of infection when
combined with vector control in a small isolated population (for
example a few thousand individuals). Such situations may occur
for example on islands, or in hypoendemic countries where
transmission is concentrated in small pockets. With the recent
reductions in transmission that have been observed in parts of
Africa [28], such settings may become increasingly common.
However, in other endemic scenarios we find that the very high
transmission rates of P. falciparum mean that the effect of mass
treatment is likely to be short-lived after the intervention is
discontinued, in agreement with previous modeling work [18].
Data from MDA field trials indicated an even more rapid post-
intervention increase in transmission than predicted by our
simulations [26]. Therefore our estimates of the duration of
impact may be optimistic although temporal variation in EIR
could also account for the discrepancies between the trial data and
our predictions. The basic case reproductive number R0 of P.
falciparum malaria (defined as the average number of secondary
cases arising in a susceptible population as a result of a single
human case over the course of their malaria infection) can be over
100 in endemic areas of Africa when conditions are favourable for
vectors [29]. This is considerably higher than other tropical
infectious diseases for which mass treatment is a common
intervention, for example trachoma (R0 estimate = 3 or less [30])
and schistosomiasis (R0 estimate = 4–5 [31]. In such areas, there is
likely to be less value in a one-off mass treatment intervention.
However if resources are available to repeat the intervention,
reductions in EIR of around 25% could be achieved by annual
MDA even in higher transmission settings (baseline slide-
prevalence between 10%–30%). Although such an intervention
could be resource-intensive, there may be potential to combine
mass treatment for malaria with mass treatment programmes for
other infections where these are in operation, such as schistoso-
miasis and trachoma [13], provided the timing of a combined
MDA has a good impact on seasonal transmission.
Mass treatment can furthermore speed up the reduction in
prevalence achieved by vector control. In a limited number of low-
to-medium transmission settings with small population sizes which
Figure 2. Strategy options for mass treatment. (A) Three scenarios of seasonal mosquito densities simulated by the model: green line =highly
seasonal: 96% of infectious bites occur in the peak 3 months; red line =moderately seasonal: 50% of infectious bites occur in the peak 3 months; blue
line = not seasonal (for comparison). (B)&(C) Example simulations showing the impact of MDA on slide-prevalence in a scenario of highly seasonal
transmission if carried out (B) blue line: prior to the rise in mosquito densities (month 3 in this simulation) as shown in (A), versus (C) orange line: just
prior to the peak of the transmission season (month 6 in this simulation). Baseline slide-prevalence in the absence of MDA is shown in gray for
comparison. (D)&(E) Model-estimated cumulative % infectious bites averted per person after 1 round of mass treatment over the following 2 years (D)
comparing different antimalarial types and (E) comparing different screening criteria used to allocate treatment, in a scenario of moderate
transmission intensity (baseline slide-prevalence = 15%) with moderate seasonal variation (as in Figure 2A). Mass treatment is carried out prior to the
high transmission season. ‘Short-acting’ = 10 days prophylaxis, ‘long-acting’ = 30 days prophylaxis. MDA=no screening; MSAT PCR= PCR-positive
individuals are treated; MSAT M=microscopy-positive individuals are treated; MSAT M1=microscopy detects all those in the more infectious A and D
states in the model and not those in the U state (microscopy sensitivity = 58% in the scenario shown); MSAT M2=microscopy sensitivity is 75% for
infected individuals regardless of infection state (D, A or U); MSAT M3=microscopy sensitivity is 50% for infected individuals regardless of infection
state (D, A or U).
doi:10.1371/journal.pone.0020179.g002
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are isolated from other endemic areas, it may be appropriate to
consider a short term intense attack on the parasite population
using a number of closely spaced mass treatment rounds
accompanied by vector control to aim for local elimination.
However such areas would remain highly receptive to imported
parasites once the vector population recovered. It would be
important to prevent incoming infections by screening and
treatment of visitors. Such a strategy has proved successful in
Aneityum in Vanuatu, where malaria was eliminated from a small
island population (n =,700) by scaling up insecticide-treated nets
and using 9 rounds of MDA [12].
We demonstrate that MSAT using microscopy as a screening
tool may have a lower impact than MDA, but our results are
highly sensitive to the assumed infectivity of individuals who test
microscopy-negative despite having parasitaemia. A limited
number of studies suggest infectivity among these individuals is
low [32], however submicroscopic infections can be very common
[33] and additional studies on their contribution to the infectious
reservoir would be valuable for assessing the potential impact of
MSAT. We used the scenario of microscopy testing because
detailed data were available on microscopy versus PCR prevalence
by age [21]. We did not have the equivalent data for rapid
diagnostic tests which are more likely to be used in the field. Rapid
diagnostic tests may have a lower sensitivity than microscopy for
detecting asymptomatic infections [34].
Our analysis finds that gametocytocidal treatments could be
highly beneficial for mass treatment, particularly when combined
with a long-acting drug. However, the risk of adverse reactions
would need to be carefully considered, particularly for primaquine
[35]. Furthermore, mass treatment programmes could increase
drug pressure for the parasite population since asymptomatic and
non-infected individuals are administered with a full curative dose
of antimalarials that they otherwise would not have received. This
increases the chance of malaria parasites encountering sub-
therapeutic levels of long-acting drugs [36]. Ideally, antimalarials
used in any mass treatment programmes would not be regularly
used as first or second line treatments for symptomatic cases, nor
would be likely to be components of future treatment regimens. It
is possible that under certain conditions, specifically if transmission
is very low, if nearly all malaria infections are symptomatic, and
there is a high coverage of case management with the
recommended treatment, mass treatment with the same drug
may not add greatly to the selection pressure already in place as
long as good adherence to the full treatment regimen can be
achieved. However this requires confirmation through further
field-based and theoretical studies, and in many endemic areas it
would currently be challenging to achieve such conditions. Using
MSAT rather than MDA may reduce selection pressure slightly,
by reducing the number of individuals who have residual drug in
their blood after the intervention has ended. [37].
Using our model, we were able to simulate the impact of
multiple rounds of MDA in a published field trial reasonably well.
However the rise in prevalence 3 months after the end of the
intervention occurred more quickly than we estimated. This may
be because we only had EIR data during the period of the MDA
intervention, and it is likely that mosquito densities and the
Figure 3. Potential for elimination by mass treatment. (A) Example simulation of a mass treatment programme in a non-seasonal scenario
where multiple rounds of MDA are carried out, and the interval in between treatment rounds is less (every 4 months) or more (every 6 weeks) than
the critical interval required to achieve ,0.1% slide prevalence. (B) Model-estimated minimum frequency of mass treatment required in a large
population to bring slide-prevalence to 0.1% or less for at least 50 consecutive days in non-seasonal settings: MDA versus MSAT with PCR as a
screening tool. (C) Model-estimated annual mean slide-prevalence after 10 years of MDA repeated every year or every 6 months, according to
baseline slide-prevalence prior to intervention. Moderate seasonality is assumed (see Figure 2A). D) example stochastic simulations of transmission
over time assuming a small human population (n = 1000) with 1 round of MDA before the peak transmission season in year 1. A single simulation in
which MDA succeeds in eliminating infection locally is shown in black. E) and F) Model-estimated probability of local elimination at different
transmission intensities in a population of (E) 1000 or (F) 10,000, following MDA of different intensities. Results are based on 500 stochastic
realizations per plotted point. Moderate seasonality is assumed (see Figure 2A). All simulations in this figure assume a low level of vector control at
baseline which is maintained over time (the baseline slide-prevalence shown is in the presence of vector control).
doi:10.1371/journal.pone.0020179.g003
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resulting transmission levels were higher in the subsequent three
months compared to the previous year based on the control group
prevalence. Alternatively the underestimation may be a limitation
of our model structure. For example we do not allow for ‘rebound’
effects whereby asymptomatic cases who are treated lose short-
term immunity (premunition), making them more susceptible to
reinfection. Higher infectivity to mosquitoes during the early
stages of infection in humans would also speed up the rise in
prevalence following MDA. We identified only one other
published MDA trial in the literature which had control groups
and did not combine MDA with interventions against the vector
[38]. Although we did not use this study for validation, it reported
a similar swift rise in transmission after the MDA intervention
finished. After one round of MDA using SP-artesunate, the
number of clinical attacks in the villages receiving MDA remained
lower for only one month after the intervention. However, again
the EIR at the time was uncertain and there were strong seasonal
dynamics. It would be informative for further trials to be done in
lower transmission areas with follow up of the study populations
and control groups for several months after the end of mass
treatment.
One limitation of the analysis presented here is that the model
does not include spatial structure. We assume that a single
mosquito population interacts with a single human population,
whereas over larger populations it is likely that individual
mosquitoes bite only on humans within a relatively short distance.
Movement of people may reintroduce infection in the area where
MDA is undertaken. In general our results are more pessimistic
about the ability of mass treatment to achieve elimination at a
given initial transmission intensity than those generated by
previous models [18,39]. This is likely to be due in part to the
inclusion of heterogeneous exposure of the human population to
vector biting, which makes it more difficult to eliminate infection
through establishment of ‘hotspots’ of transmission [22] and is an
important feature of malaria epidemiology in the field [40,41].
Furthermore, we assumed that some individuals were repeatedly
less likely to participate in the intervention than others, therefore
reducing its impact. If there were some individuals who never
participated at all then the estimated impact of the intervention
and probabilities of elimination would be further reduced. Our
assumption of simultaneous treatment of the population which
may not be realistic. A staggered treatment distribution could
reduce the estimated effect as infection could be maintained in
parts of the population at any given time. As with any modeling
analysis, there are uncertainties in the parameters used which can
affect the conclusions. In particular, the duration and level of
infectivity of those who are treated relative to those with untreated
infection has only rarely been measured in the same study [42],
but is an important predictor of mass treatment effects. Our
estimates of the duration of infectivity are based on the duration of
gametocytaemia after treatment [43]; however this may overes-
timate the corresponding infectivity to mosquitoes which is not
well characterized [44] and infectivity may decrease over time
[45]. In particular our estimate of the duration of infectivity after
non-ACT treatment of 55 days is relatively long, however we only
assumed this duration for the result shown in Figure 2D. For all
other simulations except of the historical trial (figures 1C and 1D),
we assumed use of ACT treatment with an estimated duration of
Figure 4. Model-estimated combined impact of MDA and vector control and the potential for elimination. (A) Vector control is scaled
up in year 0, with or without 2 rounds of MDA during the first year. B), C) & D) Probabilities of local elimination in an isolated population of (B) 1000,
(C) 10,000 or (D) 500,000 using vector control alone or in combination with MDA. Transmission is moderately seasonal and MDA is given prior to the
transmission season.
doi:10.1371/journal.pone.0020179.g004
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13.4 days infectivity and an 80% reduction in transmission to
mosquitoes. If these are overestimates, then our results may be
pessimistic about mass treatment impact, however simulations
indicate that the majority of transmission after mass treatment will
probably arise from infected individuals who have not participated
in the intervention rather than from treated individuals (results not
shown).
If mass treatment becomes more widely used and approved by
WHO, control agencies will need to decide how the intervention
would fit into a wider control programme, and at what phase of
the programme it would be most useful. In all cases antimalarials
to be used for mass treatment should be very carefully selected to
minimize the risk of increasing drug resistance. Our results suggest
that in the longer term, mass treatment may be most helpful in
areas where transmission is relatively low or can be first brought to
a lower level by vector control. Where there are resources to
undertake repeated rounds of mass treatment, a sustained impact
could also be achieved in moderate-to-high transmission settings,
but the benefits of only one round of treatment can be very quickly
lost in higher transmission areas in the absence of further
intervention. Simulations such as the ones presented here can
provide some approximate estimates of the impact of mass
treatment in specific settings which can then be tested further in
the field. Our results demonstrate the importance of taking local
transmission conditions into account and considering long-term
investment in the intervention in order to make mass treatment a
successful component of a control strategy.
Supporting Information
Text S1 Further methods and result.
(DOC)
Acknowledgments
We are grateful to Neil Ferguson and Maria-Gloria Basa´n´ez at Imperial
College London for all their input on model development.
Author Contributions
Conceived and designed the experiments: LCO JTG IK TDH TSC MJW
TB CJD ACG. Performed the experiments: LCO JTG. Analyzed the data:
LCO JTG. Contributed reagents/materials/analysis tools: LCO JTG.
Wrote the paper: LCO ACG. Contributed to the writing of the paper: JTG
IK TDH TSC MJW TB CJD.
References
1. Von Seidlein L, Greenwood BM (2003) Mass administrations of antimalarial
drugs. Trends Parasitol 19: 452–460.
2. Song J, Socheat D, Tan B, Dara P, Deng C, et al. (2010) Rapid and effective
malaria control in Cambodia through mass administration of artemisinin-
piperaquine. Malar J 9: 57.
3. Naidoo I, Roper C (2010) Following the path of most resistance: dhps K540E
dispersal in African Plasmodium falciparum. Trends Parasitol 26: 447–456.
4. Wernsdorfer WH (1992) The biological and epidemiological basis of drug
resistance in malaria parasites. Southeast Asian J Trop Med Public Health 23
Suppl 4: 123–129.
5. Roll Back Malaria Partnership (2008) The Global Malaria Action Plan.
6. WHO (2010) WHO Guidelines for the treatment of malaria. 2nd edition.
Geneva: WHO.
7. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P (2009) Artemisinin-based
combination therapy for treating uncomplicated malaria. Cochrane Database
Syst Rev: CD007483.
8. Najera JA (1973) Mass drug administration and DDT indoor-spraying as
antimalarial measures in the Northern savanna of Nigeria.: World Health
Organization.
9. Zulueta J, Kafuko GW, McCrae AW, Cullen JR, Pedrsen CK, et al. (1964) A
Malaria Eradication Experiment in the Highlands of Kigezi (Uganda). East Afr
Med J 41: 102–120.
10. Lakshmanacharyulu Tea (1968) Control of malaria in a river valley project. Bull
Indian Soc Malaria and Other Communicable Di 5: 94–105.
11. Singh MVea (1968) Epidemiologic study of focal outbreak of malaria in
consolidation phase area and evaluation of remedial measures in Uttar Pradesh
(India). Bull Indian Soc Malaria and Other Communicable Di 5: 207–220.
12. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, et al. (2000) Malaria
eradication on islands. Lancet 356: 1560–1564.
13. Smits HL (2009) Prospects for the control of neglected tropical diseases by mass
drug administration. Expert Rev Anti Infect Ther 7: 37–56.
14. Lietman T, Porco T, Dawson C, Blower S (1999) Global elimination of
trachoma: how frequently should we administer mass chemotherapy? Nat Med
5: 572–576.
15. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, et al. (2006) Effect
of a single mass antibiotic distribution on the prevalence of infectious trachoma.
JAMA 295: 1142–1146.
16. Lakew T, House J, Hong KC, Yi E, Alemayehu W, et al. (2009) Reduction and
return of infectious trachoma in severely affected communities in Ethiopia. PLoS
Negl Trop Dis 3: e376.
17. Macdonald G (1967) The potential value of mass treatment in malaria
eradication.: WHO. WHO/MAL/67.615 WHO/MAL/67.615.
18. Gu W, Killeen GF, Mbogo CM, Regens JL, Githure JI, et al. (2003) An
individual-based model of Plasmodium falciparum malaria transmission on the
coast of Kenya. Trans R Soc Trop Med Hyg 97: 43–50.
19. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, et al. (2009)
The last man standing is the most resistant: eliminating artemisinin-resistant
malaria in Cambodia. Malar J 8: 31.
20. Ishikawa H, Kaneko A, Ishii A (1996) Computer simulation of a malaria control
trial in Vanuatu using a mathematical model with variable vectorial capacity.
Jpn J Trop Med Hyg 24: 11–19.
21. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, et al. (2010)
Reducing Plasmodium falciparum malaria transmission in Africa: a model-based
evaluation of intervention strategies. PLoS Med 7: e1000324.
22. Woolhouse ME, Dye C, Etard JF, Smith T, Charlwood JD, et al. (1997)
Heterogeneities in the transmission of infectious agents: implications for the
design of control programs. Proc Natl Acad Sci U S A 94: 338–342.
23. WHO (2009) World Malaria Report 2009.
24. Okell LC, Ghani AC, Lyons E, Drakeley CJ (2009) Submicroscopic infection in
Plasmodium falciparum-endemic populations: a systematic review and meta-
analysis. J Infect Dis 200: 1509–1517.
25. Ghani AC, Sutherland CJ, Riley EM, Drakeley CJ, Griffin JT, et al. (2009) Loss
of population levels of immunity to malaria as a result of exposure-reducing
interventions: consequences for interpretation of disease trends. PLoS One 4:
e4383.
26. Escudie A, Hamon J, Schneider J (1962) Resultats d’une chimioprophylaxie
antipaludique de masse par l’association amino-4-quinoleine/amino-8-quinoleine
en milieu rural africain de la region de Bobo-Dioulasso (Haute Volta) 1960. Me´d
Trop 22: 268–290.
27. Bartlett M (1957) Measles periodicity and community size. J R Stat Soc A 120:
48–70.
28. O’Meara WP, Mangeni JN, Steketee R, Greenwood B (2010) Changes in the
burden of malaria in sub-Saharan Africa. Lancet Infect Dis 10: 545–555.
29. Smith DL, McKenzie FE, Snow RW, Hay SI (2007) Revisiting the basic
reproductive number for malaria and its implications for malaria control. PLoS
Biol 5: e42.
30. Ray KJ, Lietman TM, Porco TC, Keenan JD, Bailey RL, et al. (2009) When can
antibiotic treatments for trachoma be discontinued? Graduating communities in
three African countries. PLoS Negl Trop Dis 3: e458.
31. Woolhouse ME, Hasibeder G, Chandiwana SK (1996) On estimating the basic
reproduction number for Schistosoma haematobium. Trop Med Int Health 1:
456–463.
32. Coleman RE, Kumpitak C, Ponlawat A, Maneechai N, Phunkitchar V, et al.
(2004) Infectivity of asymptomatic Plasmodium-infected human populations to
Anopheles dirus mosquitoes in western Thailand. J Med Entomol 41: 201–208.
33. Shekalaghe SA, Bousema JT, Kunei KK, Lushino P, Masokoto A, et al. (2007)
Submicroscopic Plasmodium falciparum gametocyte carriage is common in an
area of low and seasonal transmission in Tanzania. Trop Med Int Health 12:
547–553.
34. Coleman RE, Maneechai N, Rachapaew N, Kumpitak C, Soyseng V, et al.
(2002) Field evaluation of the ICT Malaria Pf/Pv immunochromatographic test
for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax
endemic area in Thailand. Am J Trop Med Hyg 66: 379–383.
35. Shekalaghe S, Braak R, Daou M, Kavishe R, Bijllaardt W, et al. (2010) In
Tanzania, hemolysis after a single dose of primaquine coadministered with an
artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient
(G6PD A-) individuals. Antimicrob Agents Chemother 54: 1762–1768.
36. Stepniewska K, White NJ (2008) The pharmacokinetic determinants of the
window of selection for antimalarial drug resistance. Antimicrob Agents
Chemother.
37. White NJ, Pongtavornpinyo W (2003) The de novo selection of drug-resistant
malaria parasites. Proc Biol Sci 270: 545–554.
Mass Treatment for Malaria Control
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e20179
38. Von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, et al. (2003)
The effect of mass administration of sulfadoxine-pyrimethamine combined with
artesunate on malaria incidence: a double-blind, community-randomized,
placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg 97:
217–225.
39. White LJ, Maude RJ, Pongtavornpinyo W, Saralamba S, Aguas R, et al. (2009)
The role of simple mathematical models in malaria elimination strategy design.
Malar J 8: 212.
40. Smith T, Charlwood JD, Takken W, Tanner M, Spiegelhalter DJ (1995)
Mapping the densities of malaria vectors within a single village. Acta Trop 59:
1–18.
41. Hii JL, Smith T, Mai A, Mellor S, Lewis D, et al. (1997) Spatial and temporal
variation in abundance of Anopheles (Diptera:Culicidae) in a malaria endemic
area in Papua New Guinea. J Med Entomol 34: 193–205.
42. Dunyo S, Milligan P, Edwards T, Sutherland C, Targett G, et al. (2006)
Gametocytaemia after Drug Treatment of Asymptomatic Plasmodium falci-
parum. PLoS Clin Trials 1: e20.
43. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, et al. (2010) Revisiting
the circulation time of Plasmodium falciparum gametocytes: molecular detection
methods to estimate the duration of gametocyte carriage and the effect of
gametocytocidal drugs. Malar J 9: 136.
44. Burgess RW, Bray RS (1961) The effect of a single dose of primaquine on the
gametocytes, gametogony and sporogony of Laverania falciparum. Bull World
Health Organ 24: 451–456.
45. Lensen A, Bril A, van de Vegte M, van Gemert GJ, Eling W, et al. (1999)
Plasmodium falciparum: infectivity of cultured, synchronized gametocytes to
mosquitoes. Exp Parasitol 91: 101–103.
46. Watkins WM, Mberu EK, Winstanley PA, Plowe CV (1997) The efficacy of
antifolate antimalarial combinations in Africa: a predictive model based on
pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13: 459–464.
47. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ (2000)
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in
acute falciparum malaria. Antimicrob Agents Chemother 44: 697–704.
48. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, et al. (2008)
Duration of protection against malaria and anaemia provided by intermittent
preventive treatment in infants in Navrongo, Ghana. PLoS One 3: e2227.
49. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ (2008)
Reduction of transmission from malaria patients by artemisinin combination
therapies: a pooled analysis of six randomized trials. Malar J 7: 125.
50. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO (2010) Quantifying
the number of pregnancies at risk of malaria in 2007: a demographic study.
PLoS Med 7: e1000221.
Mass Treatment for Malaria Control
PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e20179
